Navigation Links
Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that three abstracts have been accepted for presentation at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, October 29-November 2, 2010 in Boston, Massachusetts). The abstracts being presented are on three of the company's hepatitis C clinical programs: IDX184, IDX320 and IDX375. Full abstracts can now be viewed at the AASLD website at

The accepted abstracts are as follows:

  • Lalezari, et al, "A Phase IIa Study of IDX184 in Combination with Pegylated Interferon (PegIFN) and Ribavirin (RBV) in Treatment-Naïve HCV Genotype 1-Infected Subjects" will be featured as an oral presentation on Sunday, October 31st  at 3:45 p.m.

  • Reesink, et al, "Antiviral Activity, Safety and Pharmacokinetics of IDX320, a Novel Macrocyclic HCV Protease Inhibitor, in a 3-Day Proof-of-Concept Study in Patients with Chronic Hepatitis C" will be presented in a late-breaking poster session on Monday, November 1st between 8:00 a.m. – 5:30 p.m.

  • Bruijne, et al, "Phase I Study in Healthy Volunteers and Patients with IDX375, a Novel Non-Nucleoside HCV Polymerase Inhibitor" will be presented in a poster session on Tuesday, November 2nd between 7:00 a.m. – 12:00 p.m.

  • About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to

    Forward-looking Statements  This press release contains "forward-looking statements" for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including but not limited to the statements regarding the company's future business and financial performance. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "expect," "plans," "anticipates," "will," "expects," "goal," "estimates," "projects," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements, as are expressed or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of our drug candidates, the likelihood and success of any future clinical trials involving our drug candidates or successful development of novel combinations of direct-acting antivirals for the treatment of hepatitis C. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to the following: there can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization; management's expectations could be affected by unexpected regulatory actions or delays, including the current clinical hold on IDX184 and IDX320; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaborations with Novartis Pharma AG and GlaxoSmithKline; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management's expectations are described in greater detail under the heading "Risk Factors" in each of the company's annual report on Form 10-K for the year ended December 31, 2009 and quarterly report on form 10-Q for the quarter ended June 30, 2010, as filed with the Securities and Exchange Commission (SEC) and in any subsequent periodic or current report that the company files with the SEC.

    All forward-looking statements reflect the company's estimates only as of the date of this release (unless another date is indicated) and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. While Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the company's estimates change.Idenix Pharmaceuticals Contact:Jonae Barnes (617) 224-4485 (investors)Kelly Barry (617) 995-9033 (media)

    SOURCE Idenix Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    2. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
    3. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    4. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
    5. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
    7. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
    8. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
    9. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
    10. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
    11. Hanger Orthopedic Group, Inc. Announces Third Quarter 2010 Earnings Release Conference Call
    Post Your Comments:
    (Date:12/1/2015)... Dec. 1, 2015  Athletic apparel company ... agreed to pay $1.35 million to settle Federal ... company,s copper-infused compression clothing would relieve severe and ... other diseases. Tommie Copper,s ... company and its founder and chairman Thomas ...
    (Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
    (Date:12/1/2015)... -- --> --> ... Labeling Market by Product (Reagents & Kits, Services), Applications, ... Transcription, Reverse Transcription, End Labeling), by Region - Global ... is expected to reach USD 1,925.7 Million by 2020 ... CAGR of 8.65%. Browse 77 market data ...
    Breaking Medicine Technology:
    (Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
    (Date:12/1/2015)... ... December 01, 2015 , ... ... for the care management and population health arenas, is pleased to announce that ... cost containment services, has successfully implemented the ACUITY Complete Care™ Management to back ...
    (Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
    (Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash Moradzadeh ... Man for 2015. , Angeleno Magazine is a division of Modern Luxury, ... 1994, Modern Luxury includes more than 50 magazine titles across 15 major markets. ...
    (Date:11/30/2015)... ... November 30, 2015 , ... ... announced today that it has officially launched a sleek, mobile-ready and user-centric redesigned ... his company’s new website clearly outlines the benefits that its SEO services provide ...
    Breaking Medicine News(10 mins):